期刊文献+

Kif2c在非小细胞肺癌组织中的表达及其临床意义 被引量:3

Expression of Kif2c in non-small cell lung cancer and its clinical significance
下载PDF
导出
摘要 目的探讨Kif2c在非小细胞肺癌(NSCLC)组织中的表达及临床意义。方法收集蚌埠医学院第一附属医院手术切除的原发NSCLC组织62例及相应癌旁组织30例,采用免疫组化法检测NSCLC组织及癌旁组织中Kif2c表达,并分析其表达与NSCLC临床病理特征的关系。结果 NSCLC组织中Kif2c的高表达率为75.8%(47/62),高于癌旁组织的26.7%(8/30),差异有统计学意义(P<0.01)。Kif2c蛋白表达与NSCLC临床分期、淋巴结转移有关,其中Ⅰ、Ⅱ期的Kif2c高表达率低于Ⅲ期,有淋巴结转移者的高表达率高于无淋巴结转移者,差异均有统计学意义(P<0.05);Kif2c表达与性别、年龄、原发灶大小、病理分级、组织类型等NSCLC临床病理参数均无关(P>0.05)。结论 Kif2c在NSCLC的发生、发展过程中可能发挥一定作用,有可能作为NSCLC靶向治疗的一个潜在靶点。 Objective To explore the expression and clinical significance of Kif2c in non-small cell lung cancer( NSCLC).Methods Specimens containing 62 surgically resected NSCLC tissues and 30 paracancerous tissues were selected from the First Affiliated Hospital of Bengbu Medical College. Immunohistochemical staining was applied to detect the expression of Kif2c in NSCLC tissues and paracancerous tissues. The relationship between clinical characteristics and Kif2c expression was also studied. Results The highexpression rate of Kif2c in NSCLC tissues was 75. 8%( 47 / 62),higher than 26. 7%( 8 / 30) of paracancerous tissues with significant difference( P〈0. 05). The expression of Kif2c protein was closely related to the clinical stage and lymph node metastasis of NSCLC.The high-expression rate of Kif2c in clinical stage Ⅲ was significant higher than those of stage Ⅰ-Ⅱ in NSCLC tissues( P〈0. 05). The high-expression rate of Kif2c in lymph node metastasis was significant higher than those without lymphnode metastasis( P〈0. 05). The high-expression rates of Kif2c protein in NSCLC had no relationship with sex,age,tumor size,grade and organization type( P〉0. 05).Conclusion Kif2c may play an important role in the occurrence and development of NSCLC. Kif2c can be a molecular target of NSCLC.
出处 《临床肿瘤学杂志》 CAS 2016年第6期481-484,共4页 Chinese Clinical Oncology
基金 安徽省卫生厅科研基金资助项目(09C171)
关键词 非小细胞肺癌 Kif2c 临床意义 Non-small cell lung cancer Kif2c Clinical significance
  • 相关文献

参考文献10

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics[ J]. CA Cancer J Clin, 2011, 61(2): 69-90.
  • 2Zhang L, Shao H, Huang Y, et al. PLK1 phosphorylates mitotic centromere-associated kinesin and promotes its depolymerase ac- tivity[J]. J Biol Chem, 2011, 286(4) : 3033-3046.
  • 3Gnjatic S, CaoY, Reicheh U, et al. NY-CO-58/KIF2C is over- expressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer [ J]. Int J Cancer, 2010, 127(2): 381-393.
  • 4Shao H, Huang Y, Zhang L, et al. Spatiotemporal dynamics of Aurora B-PLK1-MCAK signaling axis orchestrates kinetochore bi- orientation and faithful chromosome segregation [ J ]. Sci Rep, 2015, 5: 12204.
  • 5Friel CT, Howard J. The kinesin-13 MCAK has an unconventional ATPase cycle adapted for microtubule depolymerization [ J ]. EMBO J, 2011, 30(19) : 3928-3939.
  • 6Wang CQ, Xiang FG, Li YJ, et al. Relation between the expres- sion of mitotic centromere-associated kinesin and the progression of squamous cell carcinoma of the tongue[ J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2014, 117(3) : 353-360.
  • 7Bie L, Zhao G, Wang YP, et al. Kinesin family member 2C (KIF2C/MCAK) is a novel marker for prognosis in human gliomas[ J]. Clin Neurol Neurosurg, 2012, 114(4) : 356-360.
  • 8Shimo A, Tanikawa C, Nishidate T, et al. Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overex- pression in mammary carcinogenesis [ J ]. Cancer Sci, 2008, 99 (1) : 62-70.
  • 9Ganguly A, Yang H, Pedroza M, et a|.Mitotic ated kinesin(MCAK) mediates paclitaxel resistance [ J ]. J Biol Chem, 2011, 286(42): 36378-36384.
  • 10Sanhaji M, Friel CT, Wordeman L, et al. Mitotic centromere-as- sociated kinesin ( MCAK ) : a potential cancer drug target [ J ]. Oncotarget, 2011, 2(12): 935-947.

同被引文献19

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部